GOLDTrials.com | A Global Web Site About Investigating Dovitinib (TKI258)

GOLD Trials

The GOLD (Global Oncologic Learnings for Dovitinib) Trials are a series of global initiatives led by Novartis that encompass a broad range of malignancies, such as renal cell carcinoma (RCC), breast cancer, gastric cancer, hepatocellular carcinoma (HCC), multiple myeloma, and urothelial cancer.

Home

Welcome to GOLD Trials, a Global Web Site About Dovitinib (TKI258)

Dovitinib (TKI258) is an investigational cancer treatment in development by Novartis.

This is a global Web site for the GOLD clinical trials and is intended for healthcare professionals around the world. GOLD stands for Global Oncologic Learnings for Dovitinib.

Disclaimer:

This is an international Web site for GOLD Trials. The information on this site is not country-specific and may contain GOLD Trials information that is different from where you practice. Please contact your local Novartis Medical Science Liaison for the latest GOLD Trials information specific to your country.

Dovitinib (TKI258) is an investigational agent. Efficacy and safety have not been established. There is no guarantee that this compound will become commercially available.

Disclaimer:

Dovitinib (TKI258) is an investigational agent. Efficacy and safety have not been established. There is no guarantee that this compound will become commercially available.